GNTA

$0.80

Post-MarketAs of Mar 17, 8:00 PM UTC

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.80
Potential Upside
5%
Whystock Fair Value$0.84
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical t...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-60.15%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
12.64

Recent News

MT Newswires
Mar 17, 2026

European Equities Traded in the US as American Depositary Receipts Higher Tuesday

European equities traded in the US as American depositary receipts were rising Tuesday morning, up 1

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Insider Monkey
Feb 28, 2026

Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business

Genenta Science SPA (NASDAQ:GNTA) is among the best Italian stocks to buy in 2026. Genenta Science SPA (NASDAQ:GNTA) will hold an extraordinary shareholders meeting on March 26. This comes on the back of the company announcing a major shift in its business strategy. Genenta Science, which has all along been concentrating on biotech programs with […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Jan 2, 2026

European Equities Traded in the US as American Depositary Receipts Gain Friday

European equities traded in the US as American depositary receipts were rising on Friday morning, up

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Oct 27, 2025

US-China Trade Optimism Lifts US Equity Futures Pre-Bell

US equity futures were up ahead of Monday's opening bell as traders monitored developments surroundi

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Oct 27, 2025

Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology. This move highlights growing confidence in Genenta’s research trajectory. See our latest analysis for Genenta Science. Genenta Science's share price soared this week following the expanded Anemocyte collaboration, locking in a remarkable 1-day share price return of 91.95% and a 7-day return...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.